Acute kidney injury in liver transplant candidates: a position paper on behalf of the LIVER INTENSIVE CARE GROUP of EUROPE. by Angeli, P et al.
0,1(59$$1(67(6,2/2*,&$
(',=,21,0,1(59$0(',&$
This provisional PDF corresponds to the article as it appeared upon acceptance.
A copyedited and fully formatted version will be made available soon.
The final version may contain major or minor changes.

Subscription: Information about subscribing to Minerva Medica journals is online at:
http://www.minervamedica.it/en/how-to-order-journals.php 
Reprints and permissions: For information about reprints and permissions send an email to:
journals.dept@minervamedica.it - journals2.dept@minervamedica.it - journals6.dept@minervamedica.it 
 
 
COPYRIGHT© 2016 EDIZIONI MINERVA MEDICA

Acute kidney injury in liver transplant candidates: A
position paper on behalf of the LIVER INTENSIVE CARE
GROUP of EUROPE 
3DROR$1*(/,'LPLWUL%(=,129(5*LDQQL%,$1&2),25($QMD%,(1+2/=
-DPHV),1'/$<&DWKHULQH3$8*$0%857=.RHQ5(<17-(167HWVXUR6$.$,)XDW
+DNDQ6$1(5'DQD720(6&8*HEKDUG:(*(1(5(PPDQXHO:(,66
0LQHUYD$QHVWHVLRO2FW>(SXEDKHDGRISULQW@
MINERVA ANESTESIOLOGICA
5LYLVWDGL$QHVWHVLD5LDQLPD]LRQH7HUDSLD$QWDOJLFDH7HUDSLD,QWHQVLYD
S,661H,661
$UWLFOHW\SH5HYLHZ$UWLFOH

7KHRQOLQHYHUVLRQRIWKLVDUWLFOHLVORFDWHGDWKWWSZZZPLQHUYDPHGLFDLW
 1 
Acute kidney injury in liver transplant candidates: A position paper on behalf of the 
LIVER INTENSIVE CARE GROUP of EUROPE  
 
Authors (in alphabetical order) 
Paolo Angeli1, Dimitri Bezinover2,  Gianni Biancofiore3, Anja Bienholz4,  James Findlay,5 
Catherine Paugam Burtz6 ,  Koen Reyntjens7,  Tetsuro Sakai8,   Fuat H. Saner9, Dana 
Tomescu10 , Gebhard Wagener11  Emmanuel Weiss6 
 
Affiliations 
1. Department of Medicine, Hepatology Unit, University School of Medicine, Padova, Italy  
2. Department of Anesthesiology, Penn State Hershey Medical Center, Hershey, PA, USA 
3. Department of Transplant Anesthesia and Critical Care, Azienda Ospedaliera-Universitaria 
Pisa, Italy  
4. Department of Nephrology, University Duisburg-Essen, Germany 
5. Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA 
6. Department of anesthesia and Critical care, APHP Hopital Beaujon, Paris and University 
Paris Diderot-Paris 7, PARIS, France 
7.Department of Anesthesia, University Medical Center, Groningen, University of 
Groningen, Netherlands 
8. Department of Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 
USA 
9. Department of General, Visceral, and Transplant Surgery, University Duisburg-Essen, 
Germany 
 
 
COPYRIGHT© 2016 EDIZIONI MINERVA MEDICA 
 
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one 
copy of this Article. It is not permitted to make additional copies (either sporadically or systematically, either printed or electronic) of the Article for any purpose. It is not permitted to distribute 
the electronic copy of the article through online internet and/or intranet file sharing systems, electronic mailing or any other means which may allow access to the Article. The use of all or any 
part of the Article for any Commercial Use is not permitted. The creation of derivative works from the Article is not permitted. The production of reprints for personal or commercial use is not 
permitted. It is not permitted to remove, cover, overlay, obscure, block, or change any copyright notices or terms of use which the Publisher may post on the Article. It is not permitted to 
frame or use framing techniques to enclose any trademark, logo, or other proprietary information of the Publisher.  
 
 2 
10. Department of Anesthesiology and Critical Care, Fundeni Clinical Institute, Bucharest, 
Romania 
11. Gebhard Wagener, Department of Anesthesiology, University of Columbia , New York, 
NY, USA 
 
Correspondence to: 
dr. Prof  Fuat H. Saner 
Department of General- and Visceral- and Transplant Surgery 
Hufelandstr. 55. 45147 Essen 
Tel: 0049 201 723 84008 
Fax: 0049 201 723 1145 
Email: fuat.saner@uni-due.de 
 
 
 
Key words: 
cirrhosis, liver transplantation, acute kidney failure, timing dialysis 
 
Word account: 4,203 
 
All authors contributed on an equal basis to important tasks such as literature research, 
drafting the work, writing a section, and/or revising the work for important content; gave 
their final approval; and agreed that all parts of the manuscript ensure integrity and 
appropriate investigation at all parts of the manuscript 
 
 
COPYRIGHT© 2016 EDIZIONI MINERVA MEDICA 
 
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one 
copy of this Article. It is not permitted to make additional copies (either sporadically or systematically, either printed or electronic) of the Article for any purpose. It is not permitted to distribute 
the electronic copy of the article through online internet and/or intranet file sharing systems, electronic mailing or any other means which may allow access to the Article. The use of all or any 
part of the Article for any Commercial Use is not permitted. The creation of derivative works from the Article is not permitted. The production of reprints for personal or commercial use is not 
permitted. It is not permitted to remove, cover, overlay, obscure, block, or change any copyright notices or terms of use which the Publisher may post on the Article. It is not permitted to 
frame or use framing techniques to enclose any trademark, logo, or other proprietary information of the Publisher.  
 
 3 
ABSTRACT 
 
Acute kidney injury (AKI) is associated with high perioperative mortality. A series of 
AKI research breakthroughs are worth mentioning. First, in 2003, serum and urine 
biomarkers specific to AKI were identified. These biomarkers have contributed to early 
detection, prevention, and treatment of AKI. In 2004, AKI severity was defined with the 
Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) criteria, which was 
developed by the International Consensus Conference Workgroup of the Acute Dialysis 
Quality Initiative. In 2007, the definition was further refined by the AKI network 
classification, and in 2012 Kidney Disease Improving Global Outcomes (KDIGO) 
standardized the RIFLE criteria into AKI stages I to III. Finally, a definition of AKI 
specifically for patients with end-stage liver disease (ESLD) was established by the 
International Club of Ascites (ICA) in 2015. Overall, these definitions and standardized 
criteria provide a foundation for systematic management of patients with AKI. 
Another important challenge over the last 20 years in the management of AKI is 
establishing the optimum timing to initiate renal replacement therapy (RRT).  Previous 
evaluations did not support the use of RRT at the early stage of kidney dysfunction. Although 
a number of retrospective studies published in the last 10 to 15 years support using RRT at an 
early stage for patients with AKI, the exact indication for RRT remains unclear.  
 
Abstract word count: 219  
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Introduction 
Acute kidney injury (AKI) is associated with significantly increased short- and long-
term complications, increased mortality, and high healthcare costs 1; the reported incidence of 
this condition after liver transplantation (LT) is as high as 70% 2. 
Extensive research on AKI over the last 20 years has significantly advanced our 
understanding of this condition. In particular, perioperative risk factors associated with the 
development of AKI in LT candidates have been identified and preventive strategies and 
treatments have been developed. It is now possible for medical practitioners to recognize and 
manage AKI earlier. Another important challenge in this field over the last 20 years is 
establishing the optimum timing to initiate renal replacement therapy (RRT).   
The aim of this position paper is to provide an up-to-date overview of AKI in patients 
with end-stage liver disease (ESLD) with special emphases on diagnosis using biomarkers, 
risk factors, and treatment. 
 
Methods 
 
In order to provide the clinical community with a straightforward and updated 
document about a debated and controversial topic, the Liver Intensive Care Group of Europe 
(LICAGE) nominated a panel of well-recognized international experts who reviewed the 
available clinical literature and produced practical clinical recommendations. The initial draft 
was revised by all of the panel members so that the final version resulted from the consensus 
of the entire working group. A systematic PubMed literature search on kidney failure related 
to cirrhosis and/or TL published from 1990 to January 2016 was performed, focusing on most 
relevant studies. The level of evidence and strength of recommendation were judged 
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 5 
according to the Grading of Recommendations Assessment Development and Evaluation 
system. The strength of the evidence was classified into four levels: high (A), moderate (B), 
low (C), and very low (D) quality evidence, while that of the recommendations was divided 
into two: strong (1) and weak (2). If no clear evidence existed, the recommendations were 
based on the consensus advice of the writing committee and the expert opinion(s) reported in 
the literature. 
 
Pathophysiology of AKI in patients with ESLD 
Portal hypertension (PH) is one of most important pathophysiological mechanisms 
responsible for the development of AKI in patients with ESLD. PH is associated with 
significant modulations of splanchnic circulation and triggers systemic vasodilatation with 
reduced central blood volume 3. This leads to a drop in mean arterial pressure with 
subsequent activation of the renin-angiotensin-aldosterone system and the sympathetic 
nervous system, elevated release of vasopressin from the pituitary gland 4, and increased 
cardiac output;  all of these signs are implicated in producing hyperdynamic circulation that 
is similar to sepsis-type hemodynamics 5. These complex hemodynamic changes are 
responsible for histological myocardial modulation with subsequent systolic and diastolic 
dysfunction, defined as cirrhotic cardiomyopathy 6. 
Due to reduced renal perfusion, the glomerular filtration rate (GFR) decreases, with 
subsequent release of aldosterone and renin as well as increased release of vasopressin 7, 8. 
All these changes, in combination with low colloid osmotic pressure, result in water 
retention, ascites, fluid overload, and increased vasoconstriction of the vas afferent vessels of 
the kidney. This leads to a further reduction in renal perfusion, which puts the patient at great 
risk of developing hepatorenal syndrome (HRS) 9.  
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 6 
The systemic inflammatory response also plays a crucial role in the development of 
AKI in patients with ESLD. These patients appear to be more susceptible to systemic 
infection than patients without ESLD, and a number of pathophysiologic mechanisms 
contribute to this effect. Patients with ESLD have increased lipopolysaccharides and tumor 
necrosis factor- serum levels, which cause splanchnic dilatation 10. These increased levels, 
in combination with a decreased local immune response, damage the intestinal mucosa and 
alter local gut-associated lympathic tissue function. This leads to increased bacterial 
translocation 11. Another mechanism responsible for generalized inflammation is associated 
with ischemia-reperfusion injury during LT. The affected hepatocytes release nuclear or 
cytosolic proteins called damage-associated molecular patterns (DAMPs), which can induce 
inflammation 12. One DAMP, high-mobility group box-1 (HMGB1), is associated with a 
inflammatory response and interacts with toll-like receptors, thereby causing renal injury 12.  
It should be noted that a number of other factors can lead to kidney injury in this 
patient population. These include medications (e.g., nonsteroidal anti-inflammatory drugs 
[NSAIDs]), diuretics, angiotensin-converting enzyme) and factors that can cause 
hypovolemia, such as gastrointestinal bleeding or paracentesis without volume replacement 
13.  
Furthermore, the risk factors for AKI in patients with ESLD are nearly the same as 
those for developing HRS 14. It has been demonstrated that even a minor improvement in 
regard to GFR is associated with a higher patient survival rate 15.  
 
Diagnostic insights of AKI in patients with ESLD 
For almost 20 years, acute renal failure in patients with ESLD was defined, according 
to an ICA criterion, as an increase in serum creatinine (sCr) of 50% from baseline to a final 
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 7 
value >1.5 mg/dL (133 mol/L) 16, 17. Presently, however, ICA experts recommend using the 
Kidney Disease Improving Global Outcomes (KDIGO) criteria, which are based on changes 
in sCr, to define AKI (Table 1) 18. The definition of AKI in patients with ESLD includes an 
abrupt reduction in kidney function demonstrated by either an absolute increase in sCr of at 
least 0.3 mg/dL ( 26.4 μmol/L) in less than 48 hours or a percentage increase in sCr of at 
least 50% (a minimum increase of 1.5 from baseline) in less than seven days 19. In addition, a 
new algorithm based for managing the treatment of AKI in patients with ESLD (Fig. 1) 19 has 
been proposed. This algorithm is related to the stages of AKI and based on several 
prospective studies 14, 20-23.  
A controversial issue is how to diagnose various types of AKI in patients with ESLD 
(Table 2). It may be possible to exclude both the post-renal and the pre-renal types because 
the former type is relatively infrequent and the latter should be diagnosed and treated by the 
measures envisaged by the previously mentioned new algorithm. The crux of the problem, 
therefore, relates to differentiating between (HRS)-AKI and acute tubular necrosis (ATN) or 
intrinsic AKI. Usually in clinical practice, it is possible to determine whether   the  patient’s  
condition is (HRS)-AKI or (ATN)-AKI by applying the diagnostic criteria for HRS, 
according to the latest ICA consensus.  
 
Prognostic value of AKI in patients with ESLD 
Renal dysfunction has been demonstrated as a powerful predictor of morbidity and 
mortality in patients with ESLD. Indeed, the reported mortality of cirrhotic patients with AKI 
is as high as 90% in some studies 24. This high mortality rate correlates with the initial 
severity of AKI and the extent to which appropriate treatment can reverse it 19. The cause of 
renal failure also affects the patient’s prognosis. It has been demonstrated that the three-
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 8 
month survival probability is 73% for parenchymal nephropathy, 46% for hypovolemia-
induced AKI, 31% for renal failure associated with infection, and only 15% for HRS 25.  
Pre-LT kidney dysfunction also has an impact on post-LT prognosis 26. The survival 
benefit of LT declines as the pre-transplant sCr level increases 27.  
 
Risk Factors for AKI  
Pre-operative risk factors  
Identified in large observational studies, the main pre-operative risk factors for post-
operative AKI in LT candidates include age, pre-existing co-morbidities (diabetes mellitus 
and systemic hypertension), severity of liver disease 28 and obesity 29-31. Pre-existing renal 
disease has been identified as an independent risk factor in some studies 32, whereas other 
studies suggest that HRS may provide some protection against renal dysfunction after LT, if 
RRT was performed before LT 31, 33. Severe pre-transplant hyponatremia has recently been 
identified as correlating with a high incidence of post-operative AKI. The pathophysiological 
mechanisms are still under debate, and it is unclear whether hyponatremia is an independent 
risk factor for post-operative AKI or a consequence of pre-clinical renal impairment that went 
undetected prior to LT 34.  
 
Intra-operative risk factors  
Intra-operative blood loss and subsequent blood transfusion (especially packed red 
blood cells and fresh frozen plasma), hemodynamic variables (mean arterial pressure, 
pulmonary capillary wedge pressure, systemic vascular resistance), and intra-operative 
hypovolemia 35 are the main risk factors for AKI identified by most studies. The effect of 
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 9 
donor graft remains uncertain, but in some studies, warm ischemic time and donation after 
cardiac death are identified as the main independent risk factors 36, 37.  
 
Post-operative risk factors  
Literature focusing on risk factors for AKI in the early post-operative period is 
limited. However, the need for surgical re-intervention, hypoalbuminemia, poor graft 
function, and immunosuppression therapy seem to be the main risk factors for renal 
dysfunction after LT 38, 39.  
 
Biomarkers 
In order to be useful, a renal biomarker must detect injury rapidly, must be highly 
sensitive and specific, and its level should correlate with the extent of injury 40. Ideally, a 
biomarker for AKI is not elevated in chronic kidney disease or with pre-renal azotemia. In 
addition, there is no consensus regarding whether urinary or plasma markers are more useful. 
A plasma biomarker can detect renal injury even if the patient is anuric, and its level does not 
need to be corrected for dilution by, for example, the use of a diuretic. However, urine 
markers are generally considered more specific for detection of renal injury and less likely to 
be contaminated by release from other organs than the kidney. Considering these 
requirements, multiple novel biomarkers have been tested in different scenarios related to 
renal ischemia-reperfusion injury 41.  
 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
NGAL is a 23 kD protein that is rapidly up-regulated and can be detected early after 
renal ischemia-reperfusion injury. Several authors evaluating urinary NGAL as a marker of 
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renal injury after LT 42-44 report results similar to those reported for other situations in which 
AKI occurs, with areas under the receiver-characteristics curve of 0.8 42 and 0.87 44 for 
urinary NGAL and 0.79 for plasma NGAL 43. NGAL can be measured using point-of-care 
devices in the urine (ARCHITECT® analyzer, Abbott Diagnostics) and blood (Alere 
Triage® NGAL test) and by using routine   chemistry   analyzers   (NGAL   Test™,   BioPorto  
Diagnostics). These tests are approved for clinical use in Europe. However, FDA approval in 
the United States is pending. 
There is no evidence to date that routine measurement of either urinary or plasma 
NGAL improves outcomes after LT. However, in combination with more conventional 
markers, NGAL measurements may help determine the severity of renal injury immediately 
after surgery. 
 
Cystatin C 
Cystatin C is a low molecular protein secreted by all nucleated cells and filtrated but 
not reabsorbed by the kidney. Unlike sCr, its level reflects the GFR independent of muscle 
mass, although cystatin C increases with age 45. Given that it is not a marker of renal injury 
but of renal function, cystatin C cannot necessarily be compared with the other renal 
biomarkers. Compared with sCr, cystatin C has been shown to correlate better with GFR after 
LT 46, 47.  
 
Other markers 
Two small studies investigated the role of urinary and plasma interleukins such as IL-
6, IL-8, and IL-18 48 and of liver-type fatty acid–binding protein 49 in LT recipients. The 
studies demonstrate that these markers predict AKI with a level of accuracy similar to that 
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reported for urinary NGAL. These and other markers, such as Kidney Injury Molecule-1 
(KIM-1), have not been evaluated in larger studies of LT patients. 
 
Renal biomarker as a clinical tool 
In Europe, NGAL and Nephrocheck, both point-of-care urinary tests that each 
measure two cell-cycle arrest biomarkers (i.e., TIMP-2 and IGFBP7), are approved for 
clinical use. In the United States, only Nephrocheck is currently approved by the FDA. 
Approval for the measurement of plasma and urinary NGAL is pending. Nephrocheck has 
not been evaluated in LT recipients. 
 
LICAGE expert panel conclusions on biomarkers 
 There is currently no evidence that routine measurement of renal biomarkers after LT 
improves outcomes. However, in specific clinical situations, measuring renal 
biomarkers may aid in the decision-making process regarding how to initiate 
calcineurin inhibitors after LT (2B).  
 Urinary NGAL should be considered first, as it is the most widely analyzed of the 
approved biomarkers (2C).  
 Nephrocheck, even though approved in the US and Europe, should not be used in the 
LT population  and requires further validation (1C) 
 Cystatin C may be a useful tool to assess GFR in addition to or instead of sCr. (2B) 
 
Prevention of AKI 
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Patients with ESLD are at high risk of developing AKI, which, in turn is associated 
with a worse outcome in comparison with patients without renal dysfunction 50, 51. Taking 
into consideration the risk of developing AKI and the difficulty of early AKI identification, 
the prevention of AKI should be prioritized in patients with ESLD.  
 
General principles  
The general principles of AKI prevention have recently been updated for all patients 
at risk 52 and specifically for cirrhotic patients 19. The LICAGE   expert   panel’s  
recommendations are as follows: 
 discontinuing potentially nephrotoxic agents, including NSAIDs and vasodilators, 
when possible: (1C) 
 decreasing or withdrawing diuretic therapy and reviewing antimicrobial medications, 
particularly aminoglycosides and amphotericin: (1C) 
 monitoring the patient’s urine output and sCr closely: (1C) 
 improving the hemodynamics by using volume adjustment in patients with clinically 
suspected hypovolemia and achieving adequate perfusion pressure using pressers as 
indicated: (1B) 
 recognizing and treating bacterial infections promptly: (1B) 
 considering avoiding and/or using alternatives to radiocontrast procedures: (1B) 
 
Specific measures 
There are a number of specific measures that may help to prevent AKI in ESLD 
patients:  
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Treatment of spontaneous bacterial peritonitis (SBP) 
The LICAGE panel recommends the timely recognition and treatment of bacterial 
infections as one of most important therapeutic options for preventing AKI (1B). In patients 
with ESLD who also have SBP, this treatment includes albumin infusion in addition to 
antimicrobial medications. It has been demonstrated that this intervention helps to decrease 
the development of renal failure, thereby improving the survival rate 53.  
 
Administering albumin after paracentesis 
The LICAGE panel recommends the infusion of albumin at the time of large-volume 
paracentesis, as it decreases the incidence of post-paracentesis circulatory dysfunction and 
improves the patient’s chances of survival (1B) 54.  
 
Contrast-induced AKI 
The LICAGE panel recommends the use of radiocontrast only if absolutely needed 
and at the lowest appropriate dose. Volume expansion with isotonic solutions (or preferably 
balanced electrolytes) at the time the contrast agent is administered is recommended. The use 
of oral N-acetyl cysteine (NAC) can also be considered, although there is no clear evidence 
that NAC administration is beneficial to this population of patients 52. Contrast-induced 
nephropathy (CIN) has been challenged recently and extensively discussed in a review 55. 
The authors concluded that CIN was over-diagnosed and more related to the severity of the 
patient’s   illness   (sepsis,   septic   shock)   and to the use of nephrotoxic drugs and some 
physiologic changes that favored the occurrence of AKI. In a retrospective study, patients 
were stratified into three risk-groups: low risk (serum creatinine < 1.5 mg/dL), middle risk 
(1.5 - 2.0 mg/dL), and high risk (> 2 mg/dL). A total of 157,140 scans of 53,439 patients 
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were analyzed. After risk adjustment with a propensity score, contrast media was not found 
to be an independent risk factor for AKI 56. The AKI was more related to diminished renal 
function and general poor patients’   condition. Therefore, it seems doubtful that the 
intravenous use of contrast media causes acute renal failure in critically ill or cirrhotic 
patients. 
 
Pharmacologic prevention 
Many pharmacologic interventions such as a low doses of dopamine, fenoldopam, or 
atrial natriuretic peptide have been proposed for AKI prevention52. To date, however, none of 
these medications have been confirmed as a useful therapy, and none are recommended for 
use by the LICAGE panel.  
 
Intraoperative management 
No particular surgical technique, including the use of veno-venous bypass, has been 
proven to protect against the development of AKI 57, 58. The use of a low central venous 
pressure (CVP) technique may increase the risk of AKI 59; however, this concern was not 
confirmed in a subsequent randomized controlled trial 60. Also, the use of CVP or stroke 
volume variation to guide fluid replacement has not been demonstrated to reduce the 
incidence of AKI 61.  
 
Immunosuppression 
It is well known that calcineurin inhibitors (CNIs) can significantly affect renal 
function. Unfortunately, no protective strategy has been established. Although there are a 
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number of conflicting opinions regarding the potential renal risk mitigations by CNI 
minimization 62, none of these are supported by evidence.  
 
Intra-operative renal support during liver transplantation 
Intra-operative continuous renal replacement treatment (IO-CRRT) has become 
available only relatively recently. Thus, there is a paucity of data available on the benefits of 
IO-CRRT; the literature is mostly case reports and retrospective studies 63, 64. Impaired 
kidney function during LT used to be managed using strict fluid restriction, vasopressor 
support, and continuous metabolic adjustment. However, expanding the indications of LT 
and changes in organ allocation policy are accompanied by a significantly increased number 
of patients with pre-existing renal dysfunction. In this setting, the use of IO-CRRT seems to 
be very helpful for patient management. 
To date, three retrospective studies demonstrating that IO-CRRT can be performed 
safely with significant benefits for the patients have been published 65-67. 
 
Decision 
The decision to initiate IO-CRRT is made by the transplant team (intensivist, 
anesthesiologist, surgeon, and nephrologist) and is based on pre-operative kidney function, 
the severity of the condition, anticipated poor tolerance of intra-operative management 
(transfusion requirements, fluid administration, donor graft reperfusion), and/or anticipated 
need for post-operative CRRT 67.  
Intra-operative hemodialysis can be administered by either an ICU staff member or a 
nephrology nurse. Arterial blood gas (ABG) analysis should be performed periodically and 
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the results should be discussed with the anesthesiologist, who is responsible for fluid and 
electrolyte management intra-operatively.   
 
Dialysate-replacement solutions 
The decision whether to add bicarbonate or potassium and in what quantity or a 
dialysate or replacement solution should be made on a patient-by-patient basis. Any 
anticoagulates are not usually used in patients undergoing LT with an acceptable filter circuit 
lifespan, since there is an increased risk of bleeding associated with heparin and the potential 
toxicity associated with citrate 65. In the operating room, dialysis machines run with blood 
flow rates of 200-300 mL/hour and dialysate flow rates of 200-300 mL/hour 65. 
 
Metabolic acidosis 
Lactic acidosis is a common condition in patients during LT 68. Lack of lactate 
metabolism or excessive production of lactate are common causes of this phenomenon. 
During the anhepatic phase, all hepatic vessels are either partially or completely clamped, 
which results in significant lactate accumulation. In the neohepatic phase, lactate begins to 
metabolize at about 60 minutes after graft reperfusion. Lactic acidosis becomes more 
prominent in the presence of impaired renal function. This concomitant renal impairment 
makes managing lactic acidosis extremely difficult. In this context, IOCRRT would be very 
helpful. 
If the patient is under refractory acidosis, further therapeutic options can be instituted 
by increasing bicarbonate content in the dialysate from 35 mEq/L to 40 mEq/L. In such a 
case, blood flow should also be increased from 200 mL/h to 300 mL/h or even higher in order 
to provide a sufficient transfer of bicarbonate molecules through the filter to the patient 65. 
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Hyperkalemia 
Hyperkalemia occurs very frequently during LT. In patients with concomitant kidney 
injury, hyperkalemia can cause very serious problems during graft reperfusion including 
hemodynamic derangements 69 such as bradycardia, hypotension, and/or a rhythm disorder 
such as atrio-ventricular block 70. The standard concentration of potassium in a dialysate bag 
is 2 mEq/L. In cases of severe hyperkalemia, however, potassium-free dialysate should be 
used.  
 
Effect of intra-operative dialysis on volume management 
ESLD is associated with increased pressure and blood shunting in the splanchnic area 
71, which makes hemodynamic management very difficult—especially in the presence of 
kidney failure. Patients with ESLD have high vascular compliance combined with increased 
pooling of blood in the splanchnic circulation. This is associated with a minimal increase in 
CVP, although the patient appears hypervolemic 71. Such a characteristic of hemodynamics 
should be considered during LT when the volume status is usually monitored by CVP.  
There is an ongoing discussion regarding whether the  patient  should  be  on  the  “dry”  
side to avoid graft congestion or on the “wet”  side  to  preserve  or  improve  kidney  function  72, 
73. The anhepatic phase, when the inferior vena cava (IVC) is clamped, is considered one of 
the most challenging parts of LT. After the portal vein and the IVC are clamped, there is a 
decrease of around 50-60% of the venous return, which is accompanied by a significant drop 
in systemic blood pressure. At this stage, a volume challenge together with a vasopressor is 
required to maintain mean arterial pressure at 60-70 mmHg. However, after declamping, 
sudden volume load may result in right heart decompensation. In such a complicated 
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hemodynamic situation, IO-CRRT can achieve an optimum fluid balance during LT and help 
ensure hemodynamic stability.  
 
Recommendation 
The LICAGE panel recommends IO-CRRT as a very helpful tool for managing the 
treatment of patients with impaired kidney function during LT. All the complications 
associated with kidney dysfunction such as acidosis, hyperkalemia, and volume overload can 
be treated very safely. (1B) 
 
Timing of post-operative renal replacement therapy (RRT) 
The optimal timing for administering RRT in patients with AKI post-operatively is 
not well-defined. It has been demonstrated that early implementation of RRT can help 
achieve better control of fluid and electrolyte balance in selected patient populations than 
later implementation of RRT 74-76. At the same time, however, early initiation of RRT has 
been discouraged because of the following potential negative consequences: 
1. Complications associated with establishing vascular access, including bleeding, 
pneumothorax, and infection 
2. Slower renal recovery after surgery 77, 78 
 
In 2012, the KDIGO Working Group defined three emergency indications for the initiation of 
RRT 18: 
1. Life-threatening electrolyte disorders 
2. Metabolic acidosis that cannot be controlled with conservative therapy 
3. Hypervolemia, particularly when resulting in refractory pulmonary edema 
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General Considerations  
The RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria are 
most frequently used to determine when to initiate RRT. The current literature, however, 
presents no definitive recommendation concerning the timing of RRT initiation. Several 
retrospective studies have demonstrated a benefit associated with early RRT initiation. Carl et 
al. reviewed the survival of septic patients with AKI. The timing of RRT initiation in this 
study was based on blood urea nitrogen (BUN) level 79. Early initiation of RRT was 
associated with a superior 28-day and one-year survival rate 80. 
In a prospective trial in a surgical ICU setting, Shiao et al. demonstrated that starting 
RRT at an advanced RIFLE stage after major abdominal surgery is associated with higher 
mortality (OR 1.85) 81. However, this finding has not been confirmed by other investigators 
75. In another retrospective study, Shum et al. evaluated patient outcomes in the setting of 
severe sepsis and septic shock. The timing of RRT initiation was also determined based on 
RIFLE criteria 82. Early initiation of RRT (stage R) was not found to be superior in 
comparison to starting RRT later (stage I or F) in terms of mortality, dialysis requirements, or 
the Sequential Organ Failure Assessment (SOFA) score. It should be noted that patients in 
the late RRT group had significantly poorer kidney function compared with that of patients in 
the early RRT group, which was probably a confounding factor. A recent meta-analysis 
published by Karvellas et al. indicated that early dialysis has a beneficial effect 83. The 
criteria for starting RRT, however, differed across all the studies included in the analysis. 
Initiation of RRT was either triggered by BUN, serum creatinine, RIFLE stage, or urine 
output, such that it was not possible to compare the results reported in these studies.  
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 Only a few studies focused on evaluating the use of RRT in the setting of liver 
failure/LT have been published. Wu et al. examined the use of continuous venous-venous 
hemofiltration in patients with post-operative liver and kidney failure 84. They demonstrated 
that earlier initiation of RRT, based on pre-dialysis BUN level, is associated with improved 
ICU survival. In a retrospective study, Agopian et al. compared a variety of intra- and post-
operative outcomes in patients who had received planned, emergency, or no intra-operative 
RRT. Patients with planned RRT had significantly fewer intra-operative complications than 
those who received emergency RRT 66. 
 
Recommendations 
Based on the current literature, the LICAGE panel cannot give a general 
recommendation for beginning RRT at an early stage of AKI (1C). There is evidence, 
however, that initiating RRT earlier, i.e., at stage F or I (RIFLE criteria), than is usually the 
case at present, would be beneficial for some patients, particularly if the AKI is progressing 
rapidly 85.  
According to the KDIGO criteria, any decision pertaining to whether or not to begin 
RRT should be made based on a clinical assessment instead of on the sole basis of laboratory 
values such as those for serum creatinine or BUN 18. It is our opinion that the final decision to 
initiate RRT must be based on both clinical considerations and laboratory values. As always, 
an individualized patient-specific approach should be used. 
 
Summary 
 
This position paper highlights current knowledge of kidney failure, including efforts 
to improve kidney function in LT patients. Pre- and post-operative risk factors for AKI are 
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difficult to control; this is why the focus should be on intra-operative hemodynamics and 
avoiding nephrotoxic drugs (antibiotics and reduced use of CNI). Prospective randomized 
trials are needed to show the beneficial effect of intra-operative and/or post-operative early 
RRT. In this context, the new biomarkers would be helpful in identifying AKI earlier and 
would probably prevent dialysis-dependent kidney failure. 
 
 
Key messages: 
1. Diagnosis of AKI should be based on the KDIGO criteria. 
2. Risk factors are already known and were stratified into pre-, intra-, and post-operative 
risk factors. The pre-operative risk factors are more related to the patient’s  
predisposing factors and post-operative risk factors tend to be  difficult to control 
(immunosuppression, reoperation due to bleeding, bile leak, poor graft function). 
Therefore, focusing on intra-operative risk factors would be important to maintain an 
adequate hemodynamics (MAP  ≥  70  mmHg) and to keep inferior vena cava clamping 
(warm ischemia time for kidneys) as short as possible. 
3. Biomarkers to identify AKI at an early stage are available; however, there is a lack of 
robust data that indicates their beneficial effect in terms of avoiding AKI after LT. 
4. Intraoperative RRT may be beneficial in some selective cases; however, a general 
recommendation cannot be given. 
5. Timing of dialysis either pre- or post-operatively is still under debate. There are some 
promising studies that associate starting dialysis earlier with a better outcome, but it 
has not been proven with RCTs. The LICAGE panel, however, would prefer early 
initiation of dialysis. 
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Table 1. Current diagnostic criteria for acute kidney injury (AKI) in the general population 
and in patients with cirrhosis 
 
Table 2: International Club of Ascites (ICA-AKI) new definitions for the diagnosis and 
management of acute kidney injury in patients with cirrhosis 
 
Figure 1: Diagnosis and treatment algorithm for acute kidney injury.  
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